Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer.
| Autor: | Stoll S; Stadtspital Waid und Triemli, Zürich, Switzerland., Unger S; Division of Genetic Medicine, CHUV-Lausanne University Hospital, Lausanne, Switzerland., Azzarello-Burri S; Institut für Medizinische Genetik der Universität Zürich, Schlieren, Switzerland., Chappuis P; Division of Oncology and Division of Genetic Medicine, University Hospitals of Geneva, Switzerland., Graffeo R; Istituto Oncologico della Svizzera Italiana, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland., Pichert G; Onkozentrum Hirslanden, Zürich, Switzerland., Röthlisberger B; Genetica AG, Zürich, Switzerland., Taban F; MammoGene, Genève, Switzerland., Riniker S; Brustzentrum Kantonsspital St Gallen, Switzerland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Swiss medical weekly [Swiss Med Wkly] 2021 Sep 13; Vol. 151, pp. w30038. Date of Electronic Publication: 2021 Sep 13 (Print Publication: 2021). |
| DOI: | 10.4414/SMW.2021.w30038 |
| Abstrakt: | This paper presents the Swiss guideline for genetic counselling and testing of individuals with an increased probability for carrying mutations in high risk cancer predisposition genes, particularly BRCA1 and BRCA2. It aims to help providers of genetic counselling to identify valuable candidates for testing and serves as a basis for reimbursement claims to Swiss insurance companies. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|